Centre for Evaluation of Vaccination (CEV)
Administrative and Scientific Secretariat
Subscribe here for the VHPB e-mail service
PART I – Vaccination
PART II – Treatment
Tuesday 29 March 2022: Part I - Long term HBV vaccination
Chairs: Pierre Van Damme & Sema Mandal
16:00-16:20 Welcome and opening of the meeting
SESSION 1.1: Long-term protection of hepatitis B vaccination
16:20-16:40 Evidence based information on long-time protection - long term follow up studies
Protection and Antibody Levels 35 Years after Primary Series with Hepatitis B Vaccine and Response to a Booster Dose
Michael G Bruce
16:40-17:00 Memory immunity
Serum HBsAg clearance has minimal impact on CD8+ T cell responses in mouse models of HBV infection – practical implications for public health
SESSION 1.2: Need for a booster
17:00-17:20 Response to the hepatitis B vaccine and influence of sex, age of vaccination and time from the third dose. Meaning of the antibody value below 10 IU/L.
Chairs: Paolo Bonanni & Paige Armstrong
SESSION 1.3: Long-term impact of HBV vaccination, including success stories
17:30-17:50 Impact of more than 25 year of hepatitis B vaccination in Europe
SESSION 1.4: Threats for impact of HBV vaccination programs
17:50-18:10 Growing vaccine hesitancy on long-term vaccination coverage
18:10-19:20 Groups Discussion
19:20-19:30 Conclusions of the day
Wednesday 30 March 2022: Part I - Long term HBV treatment
Chairs: Mojca Maticic & Rui Tato Marinho
16:00-16:20 Short resume Day 1
David Fitzsimons (Rapporteur)
SESSION 2.1: Long-term treatment outcome hepatitis B
16:20-16:40 Overview of clinical management of hepatitis B and long-term outcome
Clinical management of chronic hepatitis B: A concise overview.
16:40-17:00 Consensus document of the Spanish Association for Study of the Liver on the treatment of hepatitis B virus infection (2020).
SESSION 2.2: Discontinuation of hepatitis B treatment
17:00-17:20 Treatment discontinuation: Asian perspective
17:20-17:40 Risks and Benefits of Discontinuation of Nucleos(t)ide Analogue Treatment: A Treatment Concept for Patients With HBeAg-Negative Chronic Hepatitis B.
Florian van Bömmel
17:40-18:00 Off-Therapy Response After Nucleos(t)ide Analogue Withdrawal in Patients With Chronic Hepatitis B: An International, Multicenter, Multiethnic Cohort (RETRACT-B Study).
Hirode G, Choi HSJ, Chen CH, Su TH, Seto WK, Van Hees S, Papatheodoridi M, Lens S, Wong G, Brakenhoff SM, Chien RN, Feld J, Sonneveld M, Chan HLY, Forns X, Papatheodoridis GV, Vanwolleghem T, Yuen MF, Hsu YC, Kao JH, Cornberg M, Hansen BE, Jeng, Wj, Janssen HLA and Group R-BS
SESSION 2.3: Panel discussion & closing
Chair: Thomas Vanwolleghem
18:20-19:20 Panel Discussion
The future of hepatitis B treatment - stop or go?
Panel speakers: Maria Buti / Rachel Jeng / Florian van Bömmel
19:20-19:30 Conclusions and closing of the meeting
The meeting report will be available soon.